Presenter's Information
Renu Virmani, MD
Country | USA |
Specialty | Interventional Cardiologist |
- Vulnerable Plaque: What Is It? Pathological Perspective
- Pathologic Perspective
- DCB Versus DES for SFA: Which Is Better?
- Pathology of TAVR and Mitral Devices
- Not All DCBs Are Created Equal: Side by Side Pre-clinical Safety Evaluation of Leading DCBs
- DES Failure: Pathologic Findings and Treatment
- No, It is Not Yet Ready.
- Natural History of Vulnerable Plaque: Targets for Risk Stratification
- Unique Demands of the Femoral Anatomy and Pathology and the Need for Unique Interventions
- Autopsy Studies of TAVR - What Have We Learnt?
- Late Complication: Stent Fractures and Restenosis
- Pathology of Transcatheter Aortic Valve Implantation
- Pathogenesis of Vulnerable Plaque 2013: What's New?
- Thrombosis and Inflammation in Plaque Vulnerability: What Is the Next Target for New Drugs?
- Vulnerable Plaque: Anatomic Features Linked to Future Events
- Plaque Progression and Instability: Critical Insights from Pathology
- Neoatherosclerosis: Correlates OCT/IVUS with Histology
- Histolopathologic Validation of In-stent Neoatherosclerosis
- Mechanisms of Plaque Destabilization: Pathologic Observation
- Evidence and Future Perspective for Vulnerable Plaque from Pathologic Data
- Evolving Pathologic Perspectives on the Etiology of AMI
- DES Pathobiology: Insights from Assessment of Endothelial Integrity and Function
- Why Even Favorable One-Year Data From HORIZONS Shouldn¡¯t Compel DES Usage in AMI
- Characterizing the Vulnerable Plaque: Structural Observations and Natural History Insights from the Core Pathology Laboratory
- Next Generation DES: Results from Preclinical Data
- DES Pathology Update - What We Know, What We Do Not Know
- Why Current DES Should NOT be Used Routinely During Primary AMI Angioplasty!
- The Causes of Late DES Thrombosis: a Pathologist's Viewpoint!
- New Pathologic Insights into Vulnerable Plaques
- Erosion, Intraplaque Hemorrhage: The Other Face of Vulnerability
- Pathology of Vulnerable Plaque
- DES Pathobiology Considerations: What We Know and What We Don't Know Can Hurt Us!
- The Value of Animal Models in Evaluating Pathobiologic Effects of Drug-Eluting Stents: Insights from Past Successes and Failures
- Should We Expect "Late Catch-up"(Late Restenosis) After DES Treatment-Is the Genie Already out of the Bottle? You Have Simply Postponed the Inevitable